Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Miahelsa HoldingsTSE:7129 +0.52%43 EBITDA Margin % is 14.57% as of Mar. 2026, which is 215% above its 10-year median of 4.62. GuruFocus rates TSE:7129 with a GF Score™ of 43/100 and a GF Value™ of 円1,069.22 (Fairly Valued). The stock has 1 warning sign investors should review. Among 664 Healthcare Providers & Services companies, Miahelsa Holdings ranks worse than 67.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Miahelsa Holdings's EBITDA for the
three
months ended in Mar. 2026 was 円939 Mil. Miahelsa Holdings's Revenue for the
three
months ended in Mar. 2026 was 円6,443 Mil. Therefore, Miahelsa Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 14.57%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Miahelsa Holdings EBITDA Margin % Related Terms
Miahelsa Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Miahelsa Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Miahelsa Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Miahelsa Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Miahelsa Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Miahelsa Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Miahelsa Holdings (TSE:7129) has a EBITDA Margin % of 14.57% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Miahelsa Holdings and its competitors. This is 215% above median its historical median of 4.62. Over the past decade, Miahelsa Holdings' EBITDA Margin % has ranged from 3.29 to 5.57. According to the industry distribution chart, Miahelsa Holdings ranks #449 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 67.6%.
Is Miahelsa Holdings' EBITDA Margin % too high?
Miahelsa Holdings' current EBITDA Margin % of 14.57% is 215% above median its 10-year median of 4.62. Over the past 10 years, this metric has ranged from a low of 3.29 to a high of 5.57. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Miahelsa Holdings' value of 14.57% is 42.4% above this industry median. Based on the distribution chart, Miahelsa Holdings ranks #449 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Miahelsa Holdings has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Miahelsa Holdings' EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Miahelsa Holdings ranks #449 out of 664 companies for EBITDA Margin %. This places Miahelsa Holdings in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Miahelsa Holdings' value of 14.57% is 42.4% above this benchmark. Historically, Miahelsa Holdings' own EBITDA Margin % has ranged from 3.29 to 5.57 over the past decade. While the company's 10-year median is 4.62 vs. the industry median of 10.24, Miahelsa Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Miahelsa Holdings's current EBITDA Margin % of 14.57% is 42.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Miahelsa Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Miahelsa Holdings's current EBITDA Margin % is 14.57%, which is 215% above median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Miahelsa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Miahelsa Holdings (TSE:7129) is currently considered Fairly Valued. The stock's GF Value™ is 円1,069.22, compared to a current price of 円1,159.00 — trading 8.4% above its estimated fair value. The current EBITDA Margin % is 14.57%, which is 215% above median its 10-year median of 4.62 and 42.4% above the Healthcare Providers & Services industry median of 10.24. Miahelsa Holdings' overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Miahelsa Holdings (TSE:7129), the current EBITDA Margin % is 14.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Miahelsa Holdings (TSE:7129) Overvalued in 2026?
Based on GuruFocus' analysis, Miahelsa Holdings stock appears to be overvalued.
The current stock price of 円1,159.00 is trading 8.4% above its estimated GF Value™ of 円1,069.22.
GuruFocus considers Miahelsa Holdings to be Fairly Valued.
Key valuation signals for TSE:7129:
EBITDA Margin %: 14.57% (215% above median its 10-year median of 4.62)
GF Value™: 円1,069.22 vs. price of 円1,159.00 (8.4% above fair value)
Industry Position: 42.4% above the Healthcare Providers & Services median (#449 of 664)
No single metric tells the full story. See the TSE:7129 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Miahelsa Holdings Corp, along with its subsidiaries, operates in the following reportable segments: Pharmaceutical Business, Nursing Care Business, and Childcare Business. The majority of its revenue is generated from the Pharmaceuticals Business, which operates pharmaceutical dispensaries in Japan through Nissei Pharmacy and Miahelsa Pharmacy brands, and also offers home care services. The Nursing care business mainly provides housing, medical care, nursing care, prevention, and lifestyle support for elderly people, and the Childcare segment involves the operation of licensed childcare centers. In addition, the group also operates a food business providing food suitable for all ages, from infants to the elderly.
43GF Score
Get the complete analysis for TSE:7129
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7129 has been successfully added to your 
